title: [Dermatologic adverse events of the new targeted anticancer therapies used in oncodermatology].
abstract: The management of oncology patients has been deeply modified over recent years by the development of new targeted anticancer therapies. Though these new therapies generally have a good safety profile, the skin is probably the organ most affected by their toxicity, in terms of frequency and symptom diversity. This review describes the most frequent cutaneous side effects induced by the new targeted therapies used in oncodermatology, whether they are well-established drugs such as EGF receptor inhibitors (cetuximab, erlotinib) or imatinib, or new treatments for metastatic melanoma such as selective BRAF (vemurafenib) or MEK inhibitors (selumetinib) and CTLA-4 monoclonal antibodies (ipilimumab).
authors.affiliation: Dermatologie, centre de lutte contre le cancer, institut Claudius Regaud, Toulouse, France. sibaud.vincent@claudiusregaud.fr
authors.forename: V
authors.initials: V
authors.lastname: Sibaud
authors.forename: J-P
authors.initials: JP
authors.lastname: Delord
authors.forename: C
authors.initials: C
authors.lastname: Chevreau
authors.forename: D
authors.initials: D
authors.lastname: Gangloff
authors.forename: I
authors.initials: I
authors.lastname: Garrido-Stowhas
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D058990:Molecular Targeted Therapy / Q000009:adverse effects*; D012878:Skin Neoplasms / Q000188:drug therapy*; D048490:raf Kinases / Q000037:antagonists & inhibitors
chemical_list: D000970:Antineoplastic Agents; D066246:ErbB Receptors; D048490:raf Kinases